Scarica l'app Stockscreener
48.62
3.99%
-2.02
Precedente Chiudi:
$50.64
Aprire:
$50.745
Volume 24 ore:
1.03M
Relative Volume:
0.69
Capitalizzazione di mercato:
$3.45B
Reddito:
-
Utile/perdita netta:
$-218.28M
Rapporto P/E:
-13.58
EPS:
-3.5803
Flusso di cassa netto:
$-186.55M
1 W Prestazione:
-9.26%
1M Prestazione:
+30.52%
6M Prestazione:
+105.58%
1 anno Prestazione:
+15.21%
Intervallo 1D:
$47.94
$50.84
Intervallo di 1 settimana:
$47.94
$53.76
Portata 52W:
$18.53
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Confronta VERA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
48.62 | 3.59B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | BofA Securities | Buy |
| 2025-08-04 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Quarterly Earnings: Will Vera Therapeutics Inc stock attract ESG investors2025 Market Trends & Accurate Technical Buy Alerts - moha.gov.vn
Stock Traders Purchase Large Volume of Vera Therapeutics Call Options (NASDAQ:VERA) - MarketBeat
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading - ts2.tech
Vera Therapeutics announces $200M public offering - MSN
Entry Recap: What risks investors should watch in Vera Therapeutics Inc stockJuly 2025 Momentum & Consistent Return Investment Signals - moha.gov.vn
Vera Therapeutics price target raised to $33 from $23 at Wedbush - MSN
50,000 Shares in Vera Therapeutics, Inc. $VERA Purchased by Swedbank AB - MarketBeat
450,700 Shares in Vera Therapeutics, Inc. $VERA Acquired by Capricorn Fund Managers Ltd - MarketBeat
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - ts2.tech
Vera Therapeutics (NASDAQ:VERA) Sets New 1-Year HighShould You Buy? - MarketBeat
Vera Therapeutics Earnings Notes - Trefis
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects - Sahm
Vera Therapeutics Appoints James R. Meyers to Board - MSN
Vera’s New Capital Raise and Legal Transition Might Change The Case For Investing In Vera Therapeutics (VERA) - Sahm
How risky is Vera Therapeutics Inc. stock now2025 Market Overview & Smart Swing Trading Alerts - Улправда
Weekly Earnings: How Vera Therapeutics Inc. stock valuations compare to rivalsJuly 2025 EndofMonth & Momentum Based Trading Ideas - ulpravda.ru
Recap Report: Will Vera Therapeutics Inc. stock attract ESG investorsLong Setup & Long-Term Safe Investment Plans - moha.gov.vn
Vera Therapeutics, Inc. $VERA Shares Acquired by Squarepoint Ops LLC - MarketBeat
Goldman Sachs Maintains Vera Therapeutics (VERA) Buy Recommendation - Nasdaq
Vera Therapeutics stock hits 52-week high at 51.23 USD By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Vera Therapeutics Investors Drop Short-Swing Trading Lawsuit - Bloomberg Law News
Vera Therapeutics stock hits 52-week high at 51.23 USD - Investing.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Given New $96.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Is Vera Therapeutics Inc. stock oversold or undervalued2025 Market Trends & Fast Gain Swing Alerts - Улправда
Is Vera Therapeutics Inc. stock gaining market shareProfit Target & Real-Time Buy Signal Notifications - DonanımHaber
Goldman Sachs raises Vera Therapeutics stock price target to $95 on IgAN pricing - Investing.com Canada
Vera Therapeutics stock price target raised to $66 by BofA Securities - Investing.com Canada
Will Vera Therapeutics Inc. stock maintain growth storyIndex Update & Weekly Breakout Watchlists - DonanımHaber
What risks investors should watch in Vera Therapeutics Inc. stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - DonanımHaber
How Vera Therapeutics Inc. stock valuations compare to rivalsEarnings Recap Report & Low Volatility Stock Recommendations - Улправда
Aug Closing: How Vera Therapeutics Inc. stock valuations compare to rivalsShare Buyback & Daily Technical Forecast Reports - Улправда
Vera Therapeutics Announces Departure of Chief Legal Officer - TipRanks
Vera Therapeutics, Inc. Announces Departure of Jason Carter as Chief Legal Officer, Effective December 24, 2025 - marketscreener.com
Is Vera Therapeutics Inc. stock ready for breakoutJuly 2025 Update & Real-Time Price Movement Reports - Улправда
Vera Therapeutics Executive Sells 10,000 Shares - TradingView — Track All Markets
Vera Therapeutics Inc Stock Analysis and ForecastStock Screening Results & Small Entry Cost Portfolio - earlytimes.in
Latham & Watkins Represents Vera Therapeutics in US$300 Million Offering of Common Stock - Legal Desire Media and Insights
Hudson Bay Capital Management LP Acquires Shares of 298,976 Vera Therapeutics, Inc. $VERA - MarketBeat
Patrick Enright Acquires 5,882 Shares of Vera Therapeutics (NASDAQ:VERA) Stock - MarketBeat
Enright buys Vera Therapeutics (VERA) shares worth $249,985 By Investing.com - Investing.com Canada
Enright buys Vera Therapeutics (VERA) shares worth $249,985 - Investing.com
Vera Therapeutics Director Patrick G Enright Acquires 5,882 Shares - TradingView — Track All Markets
Dir Enright Buys 5,882 ($250K) Of Vera Therapeutics Inc [VERA] - TradingView — Track All Markets
Vera Therapeutics (VERA): Valuation Check After $260 Million Stock Offering Ahead of Atacicept FDA Decision - Sahm
Vera Therapeutics (NASDAQ:VERA) Trading Up 5.3%Still a Buy? - MarketBeat
Vera Therapeutics Sees Optimism as Analysts Boost Price Targets - timothysykes.com
Vera Therapeutics (NASDAQ:VERA) Hits New 12-Month HighHere's Why - MarketBeat
Avoiding Lag: Real-Time Signals in (VERA) Movement - news.stocktradersdaily.com
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vera Therapeutics Inc Azioni (VERA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Turner William D. | Chief Regulatory Officer |
Dec 15 '25 |
Sale |
50.08 |
10,000 |
500,767 |
22,500 |
| ENRIGHT PATRICK G | Director |
Dec 11 '25 |
Buy |
42.50 |
5,882 |
249,985 |
5,882 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):